IceCure Medical Ltd. (NASDAQ:ICCM) Stock Now Rated “Hold” by Sell-Side Brokerages

Shares of IceCure Medical Ltd. (NASDAQ:ICCM) have been given a consensus recommendation of “Hold” by the five research firms that are presently covering the firm, MarketBeat reports. Two research analysts have rated the stock with a sell rating and three have given a buy rating to the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $52.50.

A number of equities analysts recently commented on the company. Wall Street Zen downgraded IceCure Medical from a “hold” rating to a “sell” rating in a research report on Saturday, September 19th. Weiss Ratings restated a “sell (e+)” rating on shares of IceCure Medical in a report on Friday, July 17th. Finally, Zacks Research downgraded IceCure Medical from a “hold” rating to a “strong sell” rating in a research note on Friday, August 14th.

IceCure Medical Trading Down 1.9%

ICCM opened at $1.54 on Thursday. IceCure Medical has a twelve month low of $1.47 and a twelve month high of $33.00. The firm has a market capitalization of $5.28 million, a PE ratio of -0.18 and a beta of 0.43. The firm’s 50-day moving average price is $2.36 and its 200 day moving average price is $5.59.

IceCure Medical (NASDAQ:ICCM) last released its quarterly earnings data on Tuesday, June 30th. The company reported ($1.60) EPS for the quarter. IceCure Medical had a negative net margin of 427.67% and a negative return on equity of 174.26%. The business had revenue of $0.91 million during the quarter. As a group, analysts predict that IceCure Medical will post -4.61 earnings per share for the current fiscal year.

IceCure Medical Company Profile

IceCure Medical Ltd. is an Israel-based medical device company that develops minimally invasive cryoablation technology for the treatment of tumors. The company’s technology uses liquid nitrogen to freeze and destroy targeted tissue, with the goal of providing an alternative to more invasive surgical procedures.

Its primary product, the ProSense system, is designed to deliver controlled cryoablation through a thin probe inserted into a tumor under image guidance. The system has been developed for use in a range of tumor types, including breast, kidney, liver, lung and bone tumors, and has received regulatory clearances and approvals for certain indications in markets including the United States and other countries.

IceCure Medical is headquartered in Caesarea, Israel, and serves healthcare providers through commercial and distribution activities in international markets, including North America, Europe and Asia.